Search

Background: Sleep apnea is highly prevalent after acute ischemic stroke (AIS) and has increased stroke-related mortality and morbidity. The conventional sleep apnea treatment is continuous positive airway pressure (CPAP) ventilation. However, it is poorly tolerated by patients and is not used in all stroke patients. This protocol describes the impact of high-flow nasal cannula (HFNC) oxygen therapy compared to nasal continuous positive airway pressure (nCPAP) ventilation or usual care on the early prognosis of patients with sleep apnea after AIS. Methods: This randomised controlled study will be conducted in the intensive care unit of the Department of Neurology at the Wuhan Union Hospital. According to the study plan, 150 patients with sleep apnea after AIS will be recruited. All patients are randomly allocated in a 1:1:1 ratio to one of three groups: the nasal catheter group (standard oxygen group), the HFNC group, and the nCPAP group. Patients receive different types of ventilation after admission to the group, and their tolerance while using the different ventilation is recorded. Patients will be followed up by telephone three months after discharge, and stroke recovery is recorded. The primary outcomes were 28-day mortality, the incidence of pulmonary infection and endotracheal intubation. Discussion: This study analyses different ventilation modalities for early interventions in patients with sleep apnea after AIS. We will investigate whether nCPAP and HFNC reduce early mortality and endotracheal intubation rates and improve distant neurological recovery in patients. Trial registration: This trial was registered at ClinicalTrials.gov (NCT05323266; 25 March 2022). [ABSTRACT FROM AUTHOR]

In this report, we have accomplished the total synthesis of two bioactive hexahydropyrroloindole (HPI) alkaloids bearing a C3a tetrasubstituted stereocenters substituted by isopentenyl. This route was based on Cu‐catalyzed cascade arylation‐alkylation sequence in one‐pot as a key step, providing Flustramine B and Debromoflustramine B with 9 steps in 37.6 % and 31.1 % overall yields, respectively. [ABSTRACT FROM AUTHOR]

A new benzamide (1) and four known compounds (2–5) were isolated from endophytic Streptomyces YIM67086, and their structures were determined as 2-amino-3,4-dihydroxy-5-methoxybenzamide (1), 4-hydroxy-3-methoxybenzoic acid (2), phenylacetic acid (3), N-acetyltyramine (4) and p-hydroxytruxinic acid (5). Compound 5 was first found in the microorganism. The antimicrobial activities of compounds 1–5 and antioxidant activity of compound 1 were investigated. [ABSTRACT FROM AUTHOR]

Four known compounds had been isolated from the Streptomyces sp. YIM66017, and their structures were elucidated by spectral analysis as 2,6-dimethoxy terephthalic acid (1), yangjinhualine A (2), α-hydroxyacetovanillone (3) and cyclo(Gly-Trp) (4). Compound 1 was isolated from natural resources for the first time, and compounds 2–4 were isolated from streptomycetes for the first time. The 2,2-diphenyl-1-picrylhydrazyl radical-scavenging activity assays showed that 1 showed higher activity than rutin with IC50 of 4.61 μg/mL and 2 showed the activity with IC50 of 57.12 μg/mL. [ABSTRACT FROM AUTHOR]